SCHEMBL7051722

SCHEMBL7051722

O=[PH2]C(O)(CSc1ccc2ccccc2c1)C(Cc1ccccc1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.43
PPARA Q07869 5/20 0.43
SIRT5 Q9NXA8 1/20 0.39
ANPEP P15144 1/20 0.39
EPHX1 P07099 1/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
PPARD Q03181 2/20 0.36
BCL2 P10415 1/20 0.35
BCL2L1 Q07817 1/20 0.35
MCL1 Q07820 1/20 0.35
BCL2A1 Q16548 1/20 0.35
CYP1A2 P05177 1/20 0.35
CPA1 P15085 2/20 0.35
CPB1 P15086 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7049620 0.88 SIRT5 (0.43) PPARGPPARASIRT5ANPEPEPHX1
SCHEMBL7047094 0.86 SIRT5 (0.46) PPARGPPARASIRT5ANPEPEPHX1
SCHEMBL7050136 0.85 CAPN1 (0.41) PPARGPPARASIRT5ANPEPEPHX1
SCHEMBL7051221 0.85 PPARG (0.44) PPARGPPARASIRT5ANPEPEPHX1
SCHEMBL7053038 0.81 PRNP (0.48) MAPTKDM4EALDH1A1LMNARXFP1
SCHEMBL7052618 0.80 METAP2 (0.39) ANPEPEPHX1MAPTHTTLMNA
SCHEMBL7049826 0.75 PPARG (0.38) PPARGPPARAANPEPEPHX1MAPT
SCHEMBL7051222 0.71 FFAR1 (0.36) PPARGPPARAKDM4EALDH1A1POLB
SCHEMBL7048093 0.70 RXFP1 (0.46) MAPTKDM4EALDH1A1POLBHTT
SCHEMBL5950810 0.68 ANPEP (0.46) PPARGPPARASIRT5ANPEPEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 PPARG 3903/4885PPARA 4492/4885SIRT5 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.